<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="118">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01556178</url>
  </required_header>
  <id_info>
    <org_study_id>2011-14612</org_study_id>
    <nct_id>NCT01556178</nct_id>
  </id_info>
  <brief_title>Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research</brief_title>
  <official_title>Collection of Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ann &amp; Robert H Lurie Children's Hospital of Chicago</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In normal patients, blood and cerebrospinal fluid (CSF) contain circulating cells and other
      molecules such as proteins and nucleic acids.  In patients with central nervous system (CNS)
      and other conditions, the levels of these molecules may be altered.  In several other
      studies at our institution, the investigators are investigating such molecules in tumor
      specimens as well as the blood and cerebrospinal fluid of pediatric patients with CNS
      tumors.  However, these levels are difficult to interpret without comparing them to levels
      in patients without CNS tumors.  The investigators propose a study to collect small amounts
      of blood and cerebrospinal fluid from pediatric patients without CNS tumors who are
      undergoing a diagnostic or therapeutic neurosurgical procedure aimed at addressing altered
      CSF dynamics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>levels of miRNAs in the blood and CSF</measure>
    <time_frame>2 yrs</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survivin and biologic markers levels in the CSF and blood</measure>
    <time_frame>2 yrs</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hydrocephalus</condition>
  <arm_group>
    <arm_group_label>Children without central nervous system tumors</arm_group_label>
    <description>Children without central nervous system tumors between the ages of 1 year and 21 years who are undergoing a neurosurgical procedure to address hydrocephalus</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood and cerebrospinal fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All children without central nervous system tumors between the ages of 1 year and 21 years
        who are undergoing a neurosurgical procedure to address hydrocephalus during which CSF
        will be obtained will be considered
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children without central nervous system tumors who are undergoing a neurosurgical
             procedure to address hydrocephalus during which CSF will be obtained

          -  Between the ages of 1 year and 21 years

          -  Patients must be having blood draws, lumbar punctures or CSF sampling from Ommaya
             reservoirs or VPS as part of routine clinical care.

        Exclusion Criteria:

          -  Patients who do not require routine blood draws and/or CSF collection as part of
             their routine clinical care

          -  Patients who are considered too ill to participate as determined by their treating
             physician

          -  Patients with documented bacterial of viral infections of the CSF, brain parenchyma
             and/or neurosurgical devices and/or

          -  Patients with suspected de-myelinating conditions

          -  Patients who are pregnant or lactating.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rishi Lulla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rishi Lulla, MD</last_name>
    <phone>773.880.4562</phone>
    <email>rlulla@childrensmemorial.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carrie Kempler, MPH</last_name>
    <phone>773.883.6186</phone>
    <email>ckempler@childrensmemorial.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Kempler, MPH</last_name>
      <phone>773-883-6186</phone>
      <email>ckempler@childrensmemorial.org</email>
    </contact>
    <contact_backup>
      <last_name>Maya Nikin</last_name>
      <phone>773.880.8171</phone>
      <email>mnikin@childrensmemorial.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rishi Lulla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fernandez-L A, Northcott PA, Taylor MD, Kenney AM. Normal and oncogenic roles for microRNAs in the developing brain. Cell Cycle. 2009 Dec 15;8(24):4049-54. Epub 2009 Dec 5.</citation>
    <PMID>19901543</PMID>
  </reference>
  <reference>
    <citation>Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008 Jul;110(1):13-21. Erratum in: Gynecol Oncol. 2010 Jan;116(1):153.</citation>
    <PMID>18589210</PMID>
  </reference>
  <reference>
    <citation>Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008 May;141(5):672-5. Epub 2008 Mar 3.</citation>
    <PMID>18318758</PMID>
  </reference>
  <reference>
    <citation>Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010 Jul 1;127(1):118-26.</citation>
    <PMID>19876917</PMID>
  </reference>
  <reference>
    <citation>Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009 Oct;58(10):1375-81. Epub 2009 Feb 6.</citation>
    <PMID>19201770</PMID>
  </reference>
  <reference>
    <citation>Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ. MicroRNAs as Novel Biomarkers for Breast Cancer. J Oncol. 2009;2009:950201. Epub 2009 Jul 20.</citation>
    <PMID>19639033</PMID>
  </reference>
  <reference>
    <citation>Zhu W, Qin W, Atasoy U, Sauter ER. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes. 2009 May 19;2:89.</citation>
    <PMID>19454029</PMID>
  </reference>
  <reference>
    <citation>Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, Loeffler JS. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol. 2002 Feb 15;20(4):1063-8.</citation>
    <PMID>11844831</PMID>
  </reference>
  <reference>
    <citation>Fangusaro JR, Jiang Y, Holloway MP, Caldas H, Singh V, Boué DR, Hayes J, Altura RA. Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer. 2005 Jan 31;92(2):359-65.</citation>
    <PMID>15655550</PMID>
  </reference>
  <reference>
    <citation>Ikeguchi M, Kaibara N. survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer. 2002 Oct 7;87(8):883-7. PubMed PMID: 12373603; PubMed Central PMCID: PMC2376173.</citation>
    <PMID>12373603</PMID>
  </reference>
  <reference>
    <citation>Ikeguchi M, Ueda T, Sakatani T, Hirooka Y, Kaibara N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol. 2002 Mar;11(1):33-40.</citation>
    <PMID>11854600</PMID>
  </reference>
  <reference>
    <citation>Monzó M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, Martín C, Font A, Barnadas A, Abad A. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1999 Jul;17(7):2100-4.</citation>
    <PMID>10561264</PMID>
  </reference>
  <reference>
    <citation>Mori A, Wada H, Nishimura Y, Okamoto T, Takemoto Y, Kakishita E. Expression of the antiapoptosis gene survivin in human leukemia. Int J Hematol. 2002 Feb;75(2):161-5.</citation>
    <PMID>11939262</PMID>
  </reference>
  <reference>
    <citation>Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer. 2002 Mar 18;86(6):886-92.</citation>
    <PMID>11953819</PMID>
  </reference>
  <reference>
    <citation>Takamizawa S, Scott D, Wen J, Grundy P, Bishop W, Kimura K, Sandler A. The survivin:fas ratio in pediatric renal tumors. J Pediatr Surg. 2001 Jan;36(1):37-42.</citation>
    <PMID>11150435</PMID>
  </reference>
  <reference>
    <citation>Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998 Mar 21;351(9106):882-3.</citation>
    <PMID>9525374</PMID>
  </reference>
  <reference>
    <citation>Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, Nakagawara A. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000 Feb 3;19(5):617-23.</citation>
    <PMID>10698506</PMID>
  </reference>
  <reference>
    <citation>Ito R, Asami S, Motohashi S, Ootsuka S, Yamaguchi Y, Chin M, Shichino H, Yoshida Y, Nemoto N, Mugishima H, Suzuki T. Significance of survivin mRNA expression in prognosis of neuroblastoma. Biol Pharm Bull. 2005 Apr;28(4):565-8.</citation>
    <PMID>15802787</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <lastchanged_date>March 15, 2012</lastchanged_date>
  <firstreceived_date>February 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Rishi Lulla</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hydrocephalus</keyword>
  <keyword>Survivin</keyword>
  <keyword>miRNA</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Hydrocephalus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
